Nothing Special   »   [go: up one dir, main page]

EP4089082A4 - Chinolinverbindungen - Google Patents

Chinolinverbindungen Download PDF

Info

Publication number
EP4089082A4
EP4089082A4 EP21756247.9A EP21756247A EP4089082A4 EP 4089082 A4 EP4089082 A4 EP 4089082A4 EP 21756247 A EP21756247 A EP 21756247A EP 4089082 A4 EP4089082 A4 EP 4089082A4
Authority
EP
European Patent Office
Prior art keywords
quinoline compounds
quinoline
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21756247.9A
Other languages
English (en)
French (fr)
Other versions
EP4089082A1 (de
Inventor
Jiansong Wang
Yang Zhang
Zhibo LUO
Rongxin Huang
Jikui SUN
Jie Li
Wentao Wu
Jian Li
Shuhui Chen
Yingxia BAO
Wei Wang
Zhoufan XIE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Baiyunshan Pharmaceutical General Factory
Original Assignee
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Baiyunshan Pharmaceutical General Factory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Baiyunshan Pharmaceutical General Factory filed Critical Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Baiyunshan Pharmaceutical General Factory
Publication of EP4089082A1 publication Critical patent/EP4089082A1/de
Publication of EP4089082A4 publication Critical patent/EP4089082A4/de
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP21756247.9A 2020-02-20 2021-02-19 Chinolinverbindungen Pending EP4089082A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010106990 2020-02-20
CN202110065553 2021-01-13
PCT/CN2021/076918 WO2021164742A1 (zh) 2020-02-20 2021-02-19 喹啉类化合物

Publications (2)

Publication Number Publication Date
EP4089082A1 EP4089082A1 (de) 2022-11-16
EP4089082A4 true EP4089082A4 (de) 2023-07-19

Family

ID=77390452

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21756247.9A Pending EP4089082A4 (de) 2020-02-20 2021-02-19 Chinolinverbindungen

Country Status (5)

Country Link
US (1) US20230312504A1 (de)
EP (1) EP4089082A4 (de)
JP (1) JP7461605B2 (de)
CN (2) CN117903123A (de)
WO (1) WO2021164742A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022255486A1 (en) 2021-04-05 2023-10-19 Halia Therapeutics, Inc. Nek7 inhibitors
WO2022226182A1 (en) 2021-04-22 2022-10-27 Halia Therapeutics, Inc. Nek7 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010101849A1 (en) * 2009-03-02 2010-09-10 Irm Llc N- (hetero)aryl, 2- (hetero)aryl-substituted acetamides for use as wnt signaling modulators
WO2017145050A1 (en) * 2016-02-23 2017-08-31 Glaxosmithkline Intellectual Property Development Limited Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer
WO2018060714A1 (en) * 2016-09-29 2018-04-05 Daiichi Sankyo Company, Limited Pyridine compound

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008520715A (ja) * 2004-11-23 2008-06-19 メルク エンド カムパニー インコーポレーテッド ナイアシン受容体アゴニスト、そのような化合物を含む組成物、および治療方法
EA021421B1 (ru) * 2008-05-23 2015-06-30 Новартис Аг Производные хинолинов и хиноксалинов в качестве ингибиторов протеинтирозинкиназы, способ их получения, содержащая их фармацевтическая композиция и способ лечения заболеваний с применением таких соединений
UA115264C2 (uk) 2013-03-15 2017-10-10 Глаксосмітклайн Інтеллектьюел Проперті Девелопмент Лімітед Піридинові похідні як інгібітори реаранжованої у процесі трансфекції (ret) кінази
KR20160055170A (ko) 2013-08-30 2016-05-17 암비트 바이오사이언시즈 코포레이션 바이아릴 아세트아미드 화합물 및 이의 사용 방법
BR112017016333A2 (pt) * 2015-01-30 2018-04-03 Univ Sydney compostos anticâncer
BR112018067538A2 (pt) 2016-03-03 2019-02-05 Univ Cornell inibidores de ire1-alfa de pequenas moléculas
SI3442980T1 (sl) * 2016-04-15 2021-11-30 Cancer Research Technology Limited Heterociklične spojine kot zaviralci RET-kinaze
CN109761899B (zh) * 2019-02-14 2022-11-15 广州六顺生物科技股份有限公司 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物
WO2021164741A1 (zh) * 2020-02-20 2021-08-26 南京明德新药研发有限公司 苯基双酰胺类化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010101849A1 (en) * 2009-03-02 2010-09-10 Irm Llc N- (hetero)aryl, 2- (hetero)aryl-substituted acetamides for use as wnt signaling modulators
WO2017145050A1 (en) * 2016-02-23 2017-08-31 Glaxosmithkline Intellectual Property Development Limited Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer
WO2018060714A1 (en) * 2016-09-29 2018-04-05 Daiichi Sankyo Company, Limited Pyridine compound

Also Published As

Publication number Publication date
JP2023512546A (ja) 2023-03-27
EP4089082A1 (de) 2022-11-16
CN117903123A (zh) 2024-04-19
CN115210226A (zh) 2022-10-18
JP7461605B2 (ja) 2024-04-04
CN115210226B (zh) 2024-01-09
WO2021164742A1 (zh) 2021-08-26
US20230312504A1 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
AU2022212151A9 (en) Pyrimidopyran compound
EP4089082A4 (de) Chinolinverbindungen
EP3909951A4 (de) Dihydroisochinolinverbindung
HK40111953A (en) Compounds
HK40117069A (zh) Rabeximod化合物
HK40117622A (en) Compounds
HK40111694A (en) Pyrazolopyridinone compounds
HK40107242A (en) Pyrazolopyridinone compounds
AU2021904268A0 (en) Compounds
AU2021904274A0 (en) Compounds
AU2021904269A0 (en) Compounds
AU2021903120A0 (en) Compounds
AU2021901886A0 (en) Compounds
AU2020902630A0 (en) Compounds
HK40111379A (zh) 含吡啶基的化合物
HK40114714A (en) Novel benzyltryptamine compounds
HK40116051A (en) Novel benzyltryptamine compounds
HK40114793A (en) Novel compounds
HK40106182A (en) Pyridyl-containing compound
HK40103406A (en) Pyridinyl substituted oxoisoindoline compounds
HK40105236A (en) Novel compounds
HK40092954A (en) Novel compounds
HK40095159A (en) Pyrimidopyran compound
HK40097508A (en) Senotherapeutic compound
EP4209555A4 (de) Verbindung

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220810

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20230621

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 405/14 20060101ALI20230615BHEP

Ipc: A61K 31/496 20060101ALI20230615BHEP

Ipc: A61K 31/4995 20060101ALI20230615BHEP

Ipc: C07D 487/08 20060101ALI20230615BHEP

Ipc: C07D 401/14 20060101ALI20230615BHEP

Ipc: A61P 35/00 20060101ALI20230615BHEP

Ipc: A61K 31/4709 20060101ALI20230615BHEP

Ipc: C07D 401/04 20060101AFI20230615BHEP